Significance of APOB/APOA1 Ratio in the Prediction of Calcific Aortic Valve Disease
<b>Background:</b> Calcific aortic valve disease (CAVD) is a prevalent heart valve disease. The ratio of two apolipoproteins with distinct functions, Apolipoprotein B/Apolipoprotein A1 (APOB/APOA1), has been proposed as a novel assessment index for the evaluation of cardiovascular diseases. The aim of this article is to discuss the role of lipid parameters such as APOB/APOA1 in CAVD and the risk factors for CAVD, to develop a predictive model for CAVD, and to evaluate the sensitivity and specificity of this model. <b>Method:</b> Patients who initially presented to the Department of Cardiology of the Second Affiliated Hospital of Dalian Medical University between 1 January 2023 and 31 December 2023 were retrospectively identified and included in the study. Patients were divided into an aortic valve calcification group (111 cases) and a control group (201 cases) based on computed tomography (CT) findings. The clinical data, laboratory examination results, and chest CT images of the patients were collected and analyzed. A variety of statistical methods were used to analyze risk factors for CAVD, to construct a CAVD prediction model, and to assess its sensitivity and specificity. <b>Results:</b> Lipid parameters APOA1, APOB/APOA1, cumulative low-density lipoprotein (LDL) exposure, and non-high-density lipoprotein/high-density lipoprotein (non-HDL/HDL) were significantly associated with aortic valve calcification. Age, history of diabetes, diastolic blood pressure (DBP), APOB/APOA1, Cystatin C (Cys-c), and neutrophil-to-lymphocyte ratio (NLR) are identified as independent risk factors for CAVD, and the combined model achieved an AUC of 0.796 for CAVD prediction, corresponding to a sensitivity of 0.769 and a specificity of 0.755. <b>Conclusion:</b> The lipid parameters APOA1, APOB/APOA1, cumulative LDL exposure, and non-HDL/HDL have been demonstrated to be associated with aortic valve calcification. Furthermore, APOB/APOA1 can be used for the prediction of CAVD, and the combination of APOB/APOA1 with age, history of diabetes, DBP, Cys-c, and NLR has better prediction performance for CAVD.
Authors
- Zhenzhu Liu (ORCID: https://orcid.org/0000-0003-1982-0220)
- Naiqian Niu (ORCID: https://orcid.org/0000-0003-4928-7666)
- Jiajie Mei (ORCID: https://orcid.org/0000-0003-4933-8216)
- Yuxing Wang (ORCID: https://orcid.org/0009-0007-8064-5114)
- Wenli Xie (ORCID: https://orcid.org/0000-0003-2123-719X)
- Lijiao Zhang (ORCID: https://orcid.org/0000-0002-7803-1056)
- Ming Yu (ORCID: https://orcid.org/0009-0004-4240-0931)
- Peng Qu (ORCID: https://orcid.org/0009-0003-6108-8384)
- Z. Geng
- Song Yang (ORCID: https://orcid.org/0009-0005-5356-1754)
- Hong-Yan Wang (ORCID: https://orcid.org/0000-0003-3582-3245)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Cardiovascular Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/cdr/5528174
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00